entertainment -WSS

entertainment

author：comprehensive 2025-09-03 03:41:16 - browse：386

Fiona Marshall, president of the Novartis research hub in Cambridge, Mass., speaks Thursday during the STAT Future Summit. STAT

Swiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy.

The hub, which is headquartered in Cambridge, Mass., and for years has been known as Novartis Institutes for BioMedical Research, or NIBR, will soon simply be known as Novartis Biomedical Research.

But that’s not the only thing that’s changing, Fiona Marshall, the hub’s president, told a virtual audience Thursday during the 2023 STAT Future Summit. The new name reflects a larger shift by the pharma giant to retool its research strategy — from one driven by the pure pursuit of scientific discovery to a tighter focus on projects likely to yield commercially successful drugs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Morphosys mixed study results for blood cancer drug

WSS

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Surge of respiratory disease in China has likely explanation

STAT Readout: Today's biotech news includes Sana and Amylyx

Childhood cancer progress stalls for Black, Hispanic kids: Report

Akero's treatment for NASH falls short in cirrhosis study

There’s no way to know how good AI health technologies are

leisure time

entertainment

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Humana CEO Bruce Broussard to step down in 2024

DIEP, the 'gold standard' of breast reconstruction, is under threat

In key trial, Verve's treatment lowers cholesterol levels in patients

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Continuity nursing helped my family in our darkest PICU moments

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

knowledge

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Congress must reauthorize a committee to support older Americans

How should state employee insurance handle Wegovy?

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Congress must reauthorize a committee to support older Americans

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

knowledge

hotspot

hotspot

Wikipedia